Zenas BioPharma (NASDAQ:ZBIO) Director Fairmount Funds Management Llc Acquires 316,219 Shares of Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Fairmount Funds Management Llc acquired 316,219 shares of the stock in a transaction that occurred on Tuesday, October 7th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $6,008,161.00. Following the transaction, the director directly owned 2,209,025 shares of the company’s stock, valued at $41,971,475. This represents a 16.71% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $27.76 on Friday. Zenas BioPharma, Inc. has a 52-week low of $5.83 and a 52-week high of $28.72. The company has a market capitalization of $1.17 billion and a PE ratio of -7.82. The business’s fifty day moving average is $18.64 and its 200 day moving average is $13.24.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.23).

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in shares of Zenas BioPharma during the first quarter valued at about $250,000. New York State Common Retirement Fund bought a new position in shares of Zenas BioPharma during the first quarter valued at about $49,000. Jefferies Financial Group Inc. bought a new position in shares of Zenas BioPharma during the first quarter valued at about $348,000. Geode Capital Management LLC grew its stake in shares of Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Zenas BioPharma by 71.3% during the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after buying an additional 8,207 shares during the last quarter.

Analysts Set New Price Targets

ZBIO has been the topic of a number of recent analyst reports. Wedbush increased their price objective on Zenas BioPharma from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Wednesday. Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Zenas BioPharma in a research note on Thursday. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.33.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.